Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 2/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 2/20 | 1.00 |
| ▸ | PRKCA | P17252 | 2/20 | 1.00 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 1.00 |
| ▸ | CSNK1D | P48730 | 2/20 | 1.00 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 1.00 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 1.00 |
| ▸ | MAPK11 | Q15759 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | RAF1 | P04049 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | FRK | P42685 | 1/20 | 1.00 |
| ▸ | MAPK9 | P45984 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL173596 | 1.00 | MAPK14 (1.00) | MAPK14PRKD3MAP4K4PRKCACSNK1A1 | |
| SCHEMBL4918359 | 1.00 | MAPK14 (1.00) | MAPK14PRKD3MAP4K4PRKCACSNK1A1 | |
| SCHEMBL30290594 | 1.00 | MAPK14 (1.00) | MAPK14PRKD3MAP4K4PRKCACSNK1A1 | |
| SCHEMBL7767926 | 0.95 | MAPK14 (0.90) | MAPK14PRKD3MAP4K4PRKCACSNK1A1 | |
| SCHEMBL7767982 | 0.92 | MAPK14 (0.84) | MAPK14PRKD3MAP4K4PRKCACSNK1A1 | |
| SCHEMBL7773635 | 0.92 | MAPK14 (0.84) | MAPK14PRKD3MAP4K4PRKCACSNK1A1 | |
| SCHEMBL29706562 | 0.91 | MAPK14 (0.83) | MAPK14PRKD3MAP4K4PRKCACSNK1A1 | |
| SCHEMBL7771968 | 0.91 | MAPK14 (0.83) | MAPK14PRKD3MAP4K4PRKCACSNK1A1 | |
| SCHEMBL7772134 | 0.91 | MAPK14 (0.83) | MAPK14PRKD3MAP4K4PRKCACSNK1A1 | |
| SCHEMBL4916787 | 0.90 | MAPK14 (0.81) | MAPK14PRKD3MAP4K4PRKCACSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1263 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720261-A1 | NOVEL CULTURE CONDITIONS FOR CLONAL EXPANSION OF NEPHRON PROGENITOR CELLS, GENERATION OF NEPHRON ORGANOIDS, AND RAPID AND SCALABLE MODELING OF POLYCYSTIC KIDNEY DISEASE | University of Southern California (US) | 2026-04-08 | — | — | EP | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| US-12370180-B2 | P38 map kinase inhibitors for treating Friedreich's ataxia | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2025-07-29 | — | — | US | claimed |
| US-20250215397-A1 | TWO-DIMENSIONAL CULTURE METHOD HAVING CLEAR CHEMICAL COMPOSITION FOR CULTURING THREE-DIMENSIONAL INTESTINAL ORGANOID-DERIVED INTESTINAL STEM CELL AGGREGATE | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2025-07-03 | — | — | US | claimed |
| CN-119698462-A | Two-dimensional culture method with definite chemical composition for culturing three-dimensional intestinal organoid derived intestinal stem cell population | 韩国生命工学研究院 | 2025-03-25 | — | — | CN | claimed |
| WO-2024258363-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | SAHIN FIKRET (TR) | 2024-12-19 | — | — | WO | claimed |
| WO-2024243567-A1 | NOVEL CULTURE CONDITIONS FOR CLONAL EXPANSION OF NEPHRON PROGENITOR CELLS, GENERATION OF NEPHRON ORGANOIDS, AND RAPID AND SCALABLE MODELING OF POLYCYSTIC KIDNEY DISEASE | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2024-11-28 | — | — | WO | claimed |
| US-20240316055-A1 | METHODS FOR TREATING LEIGH SYNDROME | DBCC RES LLC (US) | 2024-09-26 | — | — | US | claimed |
| CN-109415699-B | Preparation method of CD4CD8 double-positive T cells | 国立大学法人京都大学 | 2024-08-27 | — | — | CN | claimed |
| CN-118105493-A | Skeletal muscle generation inducer, pharmaceutical composition, kit and application thereof | 北京大学 | 2024-05-31 | — | — | CN | claimed |
| EP-0889888-A4 | NOVEL TREATMENT FOR CNS INJURIES | SMITHKLINE BEECHAM CORP (US) | 2003-01-08 | — | — | EP | claimed |
| WO-2002060869-A2 | USE OF P38 INHIBITORS FOR THE TREATMENT OF INFLAMMATION-ENHANCED COUGH | SMITHKLINE BEECHAM CORPORATION (US) | 2002-08-08 | — | — | WO | claimed |
| US-6387898-B1 | USING IMIDAZOLE COMPOUND | SMITHKLINE BEECHAM CORPORATION | 2002-05-14 | — | — | US | claimed |
| WO-2002032862-A2 | USE OF P38 INHIBITORS FOR THE TREATMENT OF SMOKE INHALATION | SMITHKLINE BEECHAM CORPORATION (US) | 2002-04-25 | — | — | WO | claimed |
| US-6096739-A | Treatment for CNS injuries | SMITHKLINE BEECHAM CORPORATION (US) | 2000-08-01 | — | — | US | claimed |
| EP-0889726-A4 | NOVEL CYCLOALKYL SUBSTITUTED IMIDAZOLES | SMITHKLINE BEECHAM CORP (US) | 1999-07-21 | — | — | EP | claimed |
| EP-0889726-A1 | NOVEL CYCLOALKYL SUBSTITUTED IMIDAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 1999-01-13 | — | — | EP | claimed |
| EP-0889888-A1 | NOVEL TREATMENT FOR CNS INJURIES | SMITHKLINE BEECHAM CORPORATION (US) | 1999-01-13 | — | — | EP | claimed |
| WO-1997035856-A1 | NOVEL TREATMENT FOR CNS INJURIES | SMITHKLINE BEECHAM CORPORATION (US) | 1997-10-02 | — | — | WO | claimed |
| WO-1997025048-A1 | NOVEL CYCLOALKYL SUBSTITUTED IMIDAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240316055-A1 | METHODS FOR TREATING LEIGH SYNDROME | ECHS1, GLS2, OAT | MAPK14 4665/4885PRKD3 2960/4885MAP4K4 3657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.